Syphilis
Conditions
Keywords
Benzathine penicillin G, Early Syphillis, HIV, Phase 4
Brief summary
This is a phase 4, randomized, open-label, multicenter trial to evaluate the efficacy of a single injected dose of Benzathine Penicillin G (BPG) 2.4 MU (Arm 1) compared to three successive weekly injected doses of BPG 2.4 MU (Arm 2) for treatment of early syphilis in human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects. The study will enroll 560 adults (to achieve 420 evaluable subjects) aged 18 years or older with untreated early syphilis (primary, secondary, or early latent). It will be conducted at 9 sites in the US and last for 48 months with patient participation duration of 12 months. The primary objective is to compare the serological response to therapy in subjects with early (primary, secondary, or early latent) syphilis treated with Benzathine Penicillin G (BPG) 2.4 million units (MU) once or weekly for three successive weeks.
Detailed description
This is a phase 4, randomized, open-label, multicenter trial to evaluate the efficacy of a single injected dose of Benzathine Penicillin G (BPG) 2.4 MU (Arm 1) compared to three successive weekly injected doses of BPG 2.4 MU (Arm 2) for treatment of early syphilis in human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects. The study will enroll 560 adults (to achieve 420 evaluable subjects) aged 18 years or older with untreated early syphilis (primary, secondary, or early latent). It will be conducted at 9 sites in the US and last for 48 months with patient participation duration of 12 months. The primary objective is to compare the serological response to therapy in subjects with early (primary, secondary, or early latent) syphilis treated with Benzathine Penicillin G (BPG) 2.4 million units (MU) once or weekly for three successive weeks. The secondary objectives are: 1) to determine if the difference in response to therapy between treatment arms by Month 6 differs among subjects with or without HIV infection; 2) to determine the impact of multiple BPG injected doses on subject compliance with study product and adherence to the corresponding scheduled visits; 3) to determine the incidence and manifestations of the Jarisch-Herxheimer reaction among subjects treated for early syphilis with BPG; 4) to collect prospective data up to Month 12 on the serological response to therapy in subjects treated for early syphilis with either BPG regimen; 5) to compare epidemiological characteristics of early syphilis among subjects with or without HIV infection.
Interventions
BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is aged 18 years or older. 2. Subject has provided informed consent. 3. Subject has untreated primary\*, secondary\*\*, or early latent\*\*\* syphilis. \*Primary syphilis is characterized by the presence of an ulcerative lesion at a potential site of inoculation (while classically solitary, shallow, painless and with an indurated, clean base, primary lesions may be multiple, may vary considerably in appearance, and/or may not be painless) or by darkfield, acceptable polymerase chain reaction (PCR), or direct fluorescence antibody-T. pallidum (DFA-TP) positive ulcers. \*\*Secondary syphilis is characterized by classical palmar/plantar rash, condylomata lata, mucous patches, etc. or by darkfield, acceptable PCR, or DFA-TP positive lesions. \*\*\*Early latent syphilis is characterized by current reactive serologic tests for syphilis (STS) and a documented non-reactive STS, or documented sexual exposure to an individual known to have primary, secondary, or early latent syphilis diagnosed within the last 12 months. 4. Subject either has a newly reactive non-treponemal test (such as an RPR test) or a history of syphilis and a current increase in RPR titer of two or more dilutions (i.e., four-fold). 5. If subject is of childbearing potential, subject has a negative urine or serum pregnancy test. 6. Subject is willing to have an human immunodeficiency virus (HIV) test, participate in HIV counseling, and return to clinic for follow-up. 7. In the opinion of the investigator, subject is able and willing to comply with study procedures, including receipt of three Benzathine Penicillin G (BPG) injected doses if randomized to Arm 2. 8. If female, subject must be of non-childbearing potential\* or must be using an acceptable method of birth control\*\* to avoid becoming pregnant. * Non-childbearing potential is defined as being post-menopausal for at least 1 year, status after bilateral tubal ligation, or status after bilateral oophorectomy, or status after hysterectomy. * Subject must agree to avoid becoming pregnant by using one of the following acceptable methods of birth control for the entire duration of participation in the trial: * Intrauterine contraceptive device; OR * Oral contraceptives; OR * Hormonal injections; OR * Hormonal implants; OR * Contraceptive patches; OR * Monogamous relationship with vasectomized partner; OR * Exclusively same-sex relationships; OR * Use of condoms by the male partner; OR * Abstinence
Exclusion criteria
1. Subject previously enrolled in this trial. 2. Subject has latent syphilis of unknown duration, late latent syphilis, or evidence of neurosyphilis, including ocular syphilis.\* \*e.g., eye pain/redness, recent ocular change, and/or changes in visual acuity 3. Subject has a known or suspected allergy or hypersensitivity to penicillin or other beta-lactam antibiotics. 4. Subject has a known or suspected sexually transmitted infection (STI) other than syphilis requiring treatment with a drug active against T. pallidum. 5. Subject has used antibiotics\* active against T. pallidum in the preceding 30 days. \*Note: the use of antimicrobials known to NOT be effective against T. pallidum (e.g., quinolones, sulfonamides, trimethoprim, metronidazole, spectinomycin) will be allowed. 6. Subject has suspected or known ongoing drug use that might interfere with study participation and follow-up treatment. 7. Subject is breastfeeding. 8. Subject has used an investigational drug in the past 30 days that might interfere with safety or efficacy assessment. \*If the subject has used any investigational drugs in the past 30 days, contact the Principal Investigator, Division of Microbiology and Infectious Diseases (DMID) Clinical Project Manager, DMID Medical Officer, and FHI 360 to confirm eligibility. 9. Subject has any other condition that, in the opinion of the investigator, would interfere with participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Participants With a Serological Response by Month 6. | Day 1 to Day 180 | Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Day 1 | Sex history in last 60 days |
| Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Day 1 | Highest level of education completed, stage of syphilis, prior syphilis history |
| Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire | Day 1 | Years of formal education |
| Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Day 1 | Sex, Ethnicity, Race |
| Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Day 1 | Age |
| The Number of Participants Who Receive All Assigned Doses Within the Assigned Visit Windows | Through Month 12 | Compliance with study product will be defined as the participant received all assigned doses within the assigned visit windows. A participant is not adherent to study product if they miss at least one dose or receive at least one dose out of the visit window. |
| The Number of Participants Who Report Jarisch-Herxheimer Reaction Manifestations | Day 1 through Day 2 | Approximately 24 hours after Visit 1, participants were contacted and evaluated for symptoms of a JHR, which included fever, chills, myalgia, weakness, flushing, worsening of skin rash, tachycardia, heart palpitations, arthralgia, nausea, headache, and dizziness, including time of onset and time of resolution of each symptom reported. |
| Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection | Day 1 to Day 180 | Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion). Serological response to therapy by Month 6 was examined among participants with and without HIV infection, |
| Number of Participants With Serological Response (Defined as Either a 4-fold or Greater Decline in Rapid Plasma Regain (RPR) Titer Compared to Baseline or Being Rapid Plasma Regain -Negative [Seroreversion]) by Month 12. | Through month 12 | Serological response to therapy by Month 12 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 12 visit window (i.e., scheduled visits up to and including the Month 12 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 12 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 12 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 12 visit window (i.e., seroreversion). |
| Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection | Through month 12 | Serological response to therapy by Month 12 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 12 visit window (i.e., scheduled visits up to and including the Month 12 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 12 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 12visit window (i.e., seroreversion). Serological response to therapy by Month 12 was examined among participants with and without HIV infection, |
| Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Through week 1 | Sex history since last visit. |
| Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Through week 2 | Sex history since last visit. |
| Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Day 1 | Gender identity, sexual orientation, sexual partner, sex history in last 60 days |
| Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Through month 3 | Sex history since last visit. |
| Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Through month 6 | Sex history since last visit. |
| Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Through month 9 | Sex history since last visit. |
| Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Through month 12 | Sex history since last visit. |
| Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Through week 1 | Sex history since last visit |
| Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Through week 2 | Sex history since last visit |
| Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Through month 1 | Sex history since last visit |
| Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Through month 3 | Sex history since last visit |
| Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Through month 6 | Sex history since last visit |
| Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Through month 9 | Sex history since last visit |
| Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Through month 12 | Sex history since last visit |
| Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Through month 1 | Sex history since last visit. |
Countries
United States
Participant flow
Recruitment details
Participants were aged 18 years or older with untreated early syphilis recruited from the communities at large around the ten clinical sites. Participants were enrolled between 31OCT2018 and 03MAR2022.
Participants by arm
| Arm | Count |
|---|---|
| One Dose BPG 2.4 MU 2.4 MU of BPG intramuscularly on Day 1 | 124 |
| Three Doses BPG 2.4 MU 2.4 MU of BPG intramuscularly weekly for three successive weeks | 125 |
| Total | 249 |
Baseline characteristics
| Characteristic | One Dose BPG 2.4 MU | Three Doses BPG 2.4 MU | Total |
|---|---|---|---|
| Age, Continuous | 35.7 years STANDARD_DEVIATION 11.8 | 34.4 years STANDARD_DEVIATION 10.2 | 35.0 years STANDARD_DEVIATION 11 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants | 4 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 116 Participants | 120 Participants | 236 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Highest Level of Education Completed Completed College (Undergraduate Degree) | 20 Participants | 35 Participants | 55 Participants |
| Highest Level of Education Completed Completed Graduate Degree | 12 Participants | 5 Participants | 17 Participants |
| Highest Level of Education Completed Completed High School | 72 Participants | 75 Participants | 147 Participants |
| Highest Level of Education Completed Completed Junior College | 15 Participants | 5 Participants | 20 Participants |
| Highest Level of Education Completed Did Not Complete High School | 5 Participants | 5 Participants | 10 Participants |
| Prior Syphilis History | 9 Participants | 13 Participants | 22 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 3 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 74 Participants | 80 Participants | 154 Participants |
| Race (NIH/OMB) More than one race | 12 Participants | 12 Participants | 24 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 35 Participants | 28 Participants | 63 Participants |
| Sex: Female, Male Female | 5 Participants | 2 Participants | 7 Participants |
| Sex: Female, Male Male | 119 Participants | 123 Participants | 242 Participants |
| Stage of Syphilis Early Latent Syphilis | 41 Participants | 42 Participants | 83 Participants |
| Stage of Syphilis Missing 'Stage of Syphilis' | 0 Participants | 1 Participants | 1 Participants |
| Stage of Syphilis Primary Syphilis | 25 Participants | 23 Participants | 48 Participants |
| Stage of Syphilis Secondary Syphilis | 58 Participants | 59 Participants | 117 Participants |
| Years of Formal Education | 14.0 years STANDARD_DEVIATION 2.2 | 14.0 years STANDARD_DEVIATION 2 | 14.0 years STANDARD_DEVIATION 2.1 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 124 | 0 / 125 |
| other Total, other adverse events | 98 / 124 | 109 / 125 |
| serious Total, serious adverse events | 1 / 124 | 2 / 125 |
Outcome results
Primary
The Number of Participants With a Serological Response by Month 6.
Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion).
Time frame: Day 1 to Day 180
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| One Dose BPG 2.4 MU | The Number of Participants With a Serological Response by Month 6. | 94 Participants |
| Three Doses BPG 2.4 MU | The Number of Participants With a Serological Response by Month 6. | 87 Participants |
Comparison: To assess the primary efficacy endpoint, the number and proportion of participants with a serological response by Month 6 and the 95% confidence interval were summarized overall and by treatment. The Farrington-Manning test at the 5% one-sided level of significance was used to test the noninferiority hypothesis. The null hypothesis for the primary objective was that the difference in proportion of participants with serological responses between the three-dose and one-dose groups was at least 10%p-value: 0.00290% CI: [-0.15, 0.03]Farrington-Manning
Secondary
Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire
Sex, Ethnicity, Race
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Black or African American | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Male | HIV-infected | 68 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Male | HIV-uninfected | 48 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Male | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Female | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Female | HIV-uninfected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Female | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Hispanic or Latino | HIV-infected | 64 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Hispanic or Latino | HIV-uninfected | 49 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Hispanic or Latino | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Hispanic or Latino | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Hispanic or Latino | HIV-uninfected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Hispanic or Latino | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Reported | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Reported | HIV-uninfected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Reported | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: American Indian or Alaskan Native | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: American Indian or Alaskan Native | HIV-uninfected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: American Indian or Alaskan Native | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Asian | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Asian | HIV-uninfected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Asian | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Native Hawaiian or Other Pacific Islander | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Native Hawaiian or Other Pacific Islander | HIV-uninfected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Native Hawaiian or Other Pacific Islander | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Black or African American | HIV-infected | 40 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Black or African American | HIV-uninfected | 32 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: White | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: White | HIV-infected | 20 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: White | HIV-uninfected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Multi-Racial | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Multi-Racial | HIV-uninfected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Multi-Racial | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Unknown | HIV-uninfected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: American Indian or Alaskan Native | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Male | HIV-infected | 83 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Asian | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Male | HIV-uninfected | 38 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: White | HIV-infected | 14 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Male | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Asian | HIV-uninfected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Female | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Multi-Racial | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Female | HIV-uninfected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Asian | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Sex: Female | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: White | HIV-uninfected | 14 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Hispanic or Latino | HIV-infected | 80 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Native Hawaiian or Other Pacific Islander | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Hispanic or Latino | HIV-uninfected | 38 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: White | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Hispanic or Latino | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Native Hawaiian or Other Pacific Islander | HIV-uninfected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Hispanic or Latino | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Unknown | HIV-uninfected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Hispanic or Latino | HIV-uninfected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Native Hawaiian or Other Pacific Islander | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Hispanic or Latino | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Multi-Racial | HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Reported | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Black or African American | HIV-infected | 57 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Reported | HIV-uninfected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Ethnicity: Not Reported | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Black or African American | HIV-uninfected | 22 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: American Indian or Alaskan Native | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Multi-Racial | HIV-uninfected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: American Indian or Alaskan Native | HIV-uninfected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | Race: Black or African American | Unknown HIV status | 1 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire
Gender identity, sexual orientation, sexual partner, sex history in last 60 days
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Non-binary | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Other | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral active | HIV-infected | 45 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans female / trans woman | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral active | Non HIV-infected | 35 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Other | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral active | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Non-binary | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal receptive | HIV-infected | 41 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Declined to respond | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal receptive | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Man | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Declined to respond | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal insertive | HIV-infected | 38 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Non-binary | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal insertive | Non HIV-infected | 22 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Declined to respond | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal insertive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans female / trans woman | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Genital/vaginal | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Men | HIV-infected | 59 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Genital/vaginal | Non HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Other | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Men | Non HIV-infected | 29 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Always | HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Woman | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Always | Non HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Men | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Other | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Sometimes | HIV-infected | 33 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Women | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Sometimes | Non HIV-infected | 28 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans female / trans woman | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Sometimes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Women | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Never | HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Other | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Never | Non HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Women | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Never | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Man | Non HIV-infected | 46 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Yes | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans male/ trans man | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Yes | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Declined to respond | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans male/ trans man | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: No | HIV-infected | 54 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Genderqueer / gender non-conforming | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: No | Non HIV-infected | 37 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans male/ trans man | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: No | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Declined to respond | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Unknown | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans female/ trans woman | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans male / trans man | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans female/ trans woman | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: Yes | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Declined to respond | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: Yes | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans female/ trans woman | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Genderqueer / gender non-conforming | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: No | HIV-infected | 69 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Multiple | HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: No | Non HIV-infected | 49 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Heterosexual / straight | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: No | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Multiple | Non HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: Yes | HIV-infected | 30 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Woman | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: Yes | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Multiple | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: Yes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Heterosexual / straight | Non HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: No | HIV-infected | 40 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Other | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: No | Non HIV-infected | 36 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Genderqueer / gender non-conforming | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Other | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Positive | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Heterosexual / straight | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Positive | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Other | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Positive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans male / trans man | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Negative | HIV-infected | 29 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Declined to respond | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Negative | Non HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Homosexual / gay / lesbian | HIV-infected | 58 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Negative | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Declined to respond | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: Yes | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Multiple | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: Yes | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Declined to respond | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Homosexual / gay / lesbian | Non HIV-infected | 30 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: No | HIV-infected | 63 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Yes | HIV-infected | 57 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: No | Non HIV-infected | 51 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Man | HIV-infected | 67 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: No | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Yes | Non HIV-infected | 47 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: Yes | HIV-infected | 30 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Homosexual / gay / lesbian | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: Yes | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Yes | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: Yes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Multiple | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: No | HIV-infected | 40 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: No | HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation: Bisexual | HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: No | Non HIV-infected | 36 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans male / trans man | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Positive | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation: Bisexual | Non HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Positive | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Unknown | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Positive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Multiple | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Negative | HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Unknown | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Negative | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation: Bisexual | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Negative | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: Yes | HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Woman | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: Yes | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral receptive | HIV-infected | 43 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: No | HIV-infected | 66 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Other | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: No | Non HIV-infected | 51 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral receptive | Non HIV-infected | 37 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: No | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: No | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Man | HIV-infected | 81 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Man | Non HIV-infected | 37 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Man | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Woman | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Woman | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Woman | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans male / trans man | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans male / trans man | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans male / trans man | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans female / trans woman | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans female / trans woman | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Trans female / trans woman | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Genderqueer / gender non-conforming | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Genderqueer / gender non-conforming | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Genderqueer / gender non-conforming | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Multiple | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Multiple | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Multiple | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Non-binary | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Non-binary | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Non-binary | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Other | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Other | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Other | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Declined to respond | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Declined to respond | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Gender Identity : Declined to respond | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Heterosexual / straight | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Heterosexual / straight | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Heterosexual / straight | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Homosexual / gay / lesbian | HIV-infected | 69 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Homosexual / gay / lesbian | Non HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Homosexual / gay / lesbian | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation: Bisexual | HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation: Bisexual | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation: Bisexual | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Other | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Other | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Other | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Declined to respond | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Declined to respond | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Orientation : Declined to respond | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Men | HIV-infected | 71 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Men | Non HIV-infected | 27 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Men | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Women | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Women | Non HIV-infected | 8 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Women | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans male/ trans man | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans male/ trans man | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans male/ trans man | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans female/ trans woman | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans female/ trans woman | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Trans female/ trans woman | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Multiple | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Multiple | Non HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Multiple | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Other | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Other | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Other | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Declined to respond | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Declined to respond | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual Partner: Declined to respond | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Yes | HIV-infected | 72 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Yes | Non HIV-infected | 36 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Yes | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: No | HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: No | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Unknown | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Sexual intercourse in past 60 days: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral receptive | HIV-infected | 66 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral receptive | Non HIV-infected | 31 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral receptive | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral active | HIV-infected | 58 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral active | Non HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Oral active | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal receptive | HIV-infected | 55 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal receptive | Non HIV-infected | 23 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal insertive | HIV-infected | 38 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal insertive | Non HIV-infected | 15 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Rectal insertive | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Genital/vaginal | HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Genital/vaginal | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, Sites of exposure: Genital/vaginal | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Always | HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Always | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Sometimes | HIV-infected | 40 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Sometimes | Non HIV-infected | 20 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Sometimes | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Never | HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Never | Non HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If yes to sexual intercourse in past 60 days, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Yes | HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Yes | Non HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: No | HIV-infected | 53 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: No | Non HIV-infected | 29 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Unknown | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Any known exposures to an STD in the past 60 days: Unknown | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: Yes | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: Yes | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: No | HIV-infected | 77 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: No | Non HIV-infected | 39 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with gonorrhea in the past 60 days: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: Yes | HIV-infected | 42 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: Yes | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: Yes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: No | HIV-infected | 41 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: No | Non HIV-infected | 30 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for gonorrhea in the past 14 days: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Positive | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Positive | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Positive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Negative | HIV-infected | 39 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Negative | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for gonorrhea in past 14 days, Test results: Negative | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: Yes | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: Yes | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: No | HIV-infected | 77 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: No | Non HIV-infected | 39 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with chlamydia in the past 60 days: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: Yes | HIV-infected | 42 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: Yes | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: Yes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: Yes | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: No | HIV-infected | 41 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: No | Non HIV-infected | 30 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Tested for chlamydia in the past 14 days: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Positive | HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Positive | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Positive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Negative | HIV-infected | 37 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Negative | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | If tested for chlamydia in the past 14 days, Test results: Negative | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: Yes | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: No | HIV-infected | 83 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Diagnosed with any other STI in the past 60 days: No | Non HIV-infected | 40 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through month 12
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 22 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 11 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 33 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 32 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 45 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 25 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 36 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 11 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 27 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 30 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 17 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 20 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 38 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 14 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 38 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 14 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 32 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 8 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 31 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 17 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 27 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 37 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 23 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 49 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 4 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through month 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 11 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 11 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 47 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 43 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Known re-exposure | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Known re-exposure | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Known re-exposure | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 36 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 25 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 30 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 17 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 39 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 17 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 18 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 26 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 24 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 59 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 18 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 8 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 15 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 32 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 3 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through month 3
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 26 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 36 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 26 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 27 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 40 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 18 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 30 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 37 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 26 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 29 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 52 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 36 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 28 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 32 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 18 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 47 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 27 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 17 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 40 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 23 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 40 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 21 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 34 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 15 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 18 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 20 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 46 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 27 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 45 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 25 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 55 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 28 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Non HIV-infected | 0 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through month 6
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 44 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 37 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 32 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 21 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 29 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 25 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 17 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 8 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 16 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 17 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 43 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 26 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 41 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 22 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 28 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 48 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 31 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Other | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 45 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 21 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 44 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 21 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 37 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 40 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 17 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 33 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 33 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 41 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 58 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 19 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 23 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 20 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through month 9
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 18 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 17 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 37 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 27 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 28 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 8 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 32 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 37 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 25 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 38 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 17 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 11 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 49 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 25 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 29 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 30 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Known re-exposure | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Known re-exposure | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Known re-exposure | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 29 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Return worsening sx | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 45 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 15 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 38 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 40 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 33 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 17 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 16 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 43 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 15 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 42 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 54 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 19 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Since last visit, if treated for syphilis how was retreatment need determined: Local RPR results | Unknown HIV status | 0 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through week 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 43 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Non HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 61 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 58 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 42 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 67 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 35 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 7 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 67 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 36 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 1 Participants |
Secondary
Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire
Sex history since last visit.
Time frame: Through week 2
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 46 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 31 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 15 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | 3If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | 3If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | 3If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 8 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 12 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 3 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 13 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 52 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 43 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | HIV-infected | 15 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Non HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | HIV-infected | 14 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: Yes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | HIV-infected | 58 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | HIV-infected | 63 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Non HIV-infected | 23 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Sometimes | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Sexual intercourse since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Non HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Non HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | HIV-infected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral receptive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Non HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Non HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Never | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Oral active | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Non HIV-infected | 35 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | HIV-infected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | HIV-infected | 14 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Non HIV-infected | 8 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal receptive | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Non HIV-infected | 13 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Non HIV-infected | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: No | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, sites of exposure: Rectal insertive | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | 3If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | 3If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Non HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Since last visit, treated or require retreatment for syphilis apart from study treatment: No | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | 3If yes to sexual intercourse since last visit, sites of exposure: Genital/vaginal | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Non HIV-infected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to another STD since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Non HIV-infected | 6 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Any known exposures to syphilis since last visit: Unknown | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | If yes to sexual intercourse since last visit, condom or barrier for protection: Always | Unknown HIV status | 0 Participants |
Secondary
Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire
Highest level of education completed, stage of syphilis, prior syphilis history
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed junior college | HIV-uninfected | 9 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Completed graduate degree | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed high school | HIV-uninfected | 31 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Early latent syphilis | HIV-infected | 25 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed junior college | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Early latent syphilis | HIV-uninfected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Did not complete high school | HIV-uninfected | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Early latent syphilis | Unknown HIV status | 2 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed Completed college (undergraduate degree) | HIV-infected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Primary syphilis | HIV-infected | 10 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed high school | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Primary syphilis | HIV-uninfected | 14 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed Completed college (undergraduate degree) | HIV-uninfected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Primary syphilis | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed high school | HIV-infected | 40 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Secondary syphilis | HIV-infected | 35 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed Completed college (undergraduate degree) | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Secondary syphilis | HIV-uninfected | 23 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed junior college | HIV-infected | 6 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Secondary syphilis | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Completed graduate degree | HIV-infected | 7 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Prior syphilis history: Yes | HIV-infected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Did not complete high school | Unknown HIV status | 1 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Prior syphilis history: Yes | HIV-uninfected | 4 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Completed graduate degree | HIV-uninfected | 5 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Prior syphilis history: Yes | Unknown HIV status | 0 Participants |
| One Dose BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Did not complete high school | HIV-infected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Prior syphilis history: Yes | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Did not complete high school | HIV-infected | 5 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Did not complete high school | HIV-uninfected | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Did not complete high school | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed high school | HIV-infected | 52 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed high school | HIV-uninfected | 23 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed high school | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed junior college | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed junior college | HIV-uninfected | 4 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed junior college | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed Completed college (undergraduate degree) | HIV-infected | 24 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed Completed college (undergraduate degree) | HIV-uninfected | 10 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Highest level of education completed: Completed Completed college (undergraduate degree) | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Completed graduate degree | HIV-infected | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Completed graduate degree | HIV-uninfected | 3 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Completed graduate degree | Unknown HIV status | 1 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Early latent syphilis | HIV-infected | 31 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Early latent syphilis | HIV-uninfected | 9 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Early latent syphilis | Unknown HIV status | 2 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Primary syphilis | HIV-infected | 12 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Primary syphilis | HIV-uninfected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Primary syphilis | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Secondary syphilis | HIV-infected | 39 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Secondary syphilis | HIV-uninfected | 20 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Stage of syphilis: Secondary syphilis | Unknown HIV status | 0 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Prior syphilis history: Yes | HIV-infected | 11 Participants |
| Three Doses BPG 2.4 MU | Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire | Prior syphilis history: Yes | HIV-uninfected | 2 Participants |
Secondary
Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire
Age
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | HIV-uninfected | 33.4 years | Standard Deviation 11.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | HIV-infected | 37.5 years | Standard Deviation 11.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | HIV-uninfected | 30.1 years | Standard Deviation 10.2 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire | HIV-infected | 36.5 years | Standard Deviation 9.7 |
Secondary
Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire
Sex history in last 60 days
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included. Participants contributing to this outcome measure include those who answered yes to either having intercourse in the past 60 days or reported being diagnosed with at least one STI in the past 60 days.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with any other STI in the past 60 days (HIV-infected) | 3.3 days | Standard Deviation 2.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last had sexual intercourse in the past 60 days (HIV-uninfected) | 16.8 days | Standard Deviation 12.7 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with gonorrhea in the past 60 days (HIV-infected) | 1.0 days | — |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with gonorrhea in the past 60 days (HIV-uninfected) | 7.5 days | Standard Deviation 0.7 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with chlamydia in the past 60 days (HIV-infected) | 3.4 days | Standard Deviation 3.6 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last had sexual intercourse in the past 60 days (HIV-infected) | 14.3 days | Standard Deviation 13 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with chlamydia in the past 60 days (HIV-infected) | 12.7 days | Standard Deviation 21.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last had sexual intercourse in the past 60 days (HIV-infected) | 13.0 days | Standard Deviation 12.1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with gonorrhea in the past 60 days (HIV-uninfected) | 13.0 days | — |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last had sexual intercourse in the past 60 days (HIV-uninfected) | 12.6 days | Standard Deviation 10.2 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with chlamydia in the past 60 days (HIV-uninfected) | 13.0 days | — |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Days since last diagnosed with gonorrhea in the past 60 days (HIV-infected) | 24.7 days | Standard Deviation 26.4 |
Secondary
Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire
Sex history in last 60 days
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included. Participants contributing to this outcome measure include those who answered yes to either having intercourse in the past 60 days or reported being diagnosed with at least one STI in the past 60 days.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Total number of partners in the past 60 days (HIV-infected) | 4.6 count of partners | Standard Deviation 13.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Total number of partners in the past 60 days (HIV-uninfected) | 3.9 count of partners | Standard Deviation 4.8 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of new partners (HIV-infected) | 2.0 count of partners | Standard Deviation 6.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of new partners (HIV-uninfected) | 2.1 count of partners | Standard Deviation 3.4 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of regular partners (HIV-infected) | 2.0 count of partners | Standard Deviation 6.6 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of regular partners (HIV-uninfected) | 1.5 count of partners | Standard Deviation 2.7 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of occasional partners (HIV-infected) | 0.7 count of partners | Standard Deviation 1.3 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of occasional partners (HIV-uninfected) | 0.8 count of partners | Standard Deviation 1.6 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of male partners (HIV-infected) | 4.4 count of partners | Standard Deviation 13 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of male partners (HIV-uninfected) | 3.3 count of partners | Standard Deviation 4.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of female partners (HIV-infected) | 0.1 count of partners | Standard Deviation 0.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of female partners (HIV-uninfected) | 0.6 count of partners | Standard Deviation 1.4 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of female partners (HIV-infected) | 0.1 count of partners | Standard Deviation 0.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Total number of partners in the past 60 days (HIV-infected) | 3.5 count of partners | Standard Deviation 4.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of occasional partners (HIV-infected) | 0.6 count of partners | Standard Deviation 1.5 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Total number of partners in the past 60 days (HIV-uninfected) | 6.1 count of partners | Standard Deviation 9.7 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of male partners (HIV-uninfected) | 5.7 count of partners | Standard Deviation 9.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of new partners (HIV-infected) | 1.7 count of partners | Standard Deviation 2.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of occasional partners (HIV-uninfected) | 1.9 count of partners | Standard Deviation 3.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of new partners (HIV-uninfected) | 2.8 count of partners | Standard Deviation 5.2 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of female partners (HIV-uninfected) | 0.4 count of partners | Standard Deviation 0.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of regular partners (HIV-infected) | 1.4 count of partners | Standard Deviation 1.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of male partners (HIV-infected) | 3.4 count of partners | Standard Deviation 4.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire | Number of regular partners (HIV-uninfected) | 1.5 count of partners | Standard Deviation 2.7 |
Secondary
Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through month 12
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 2.1 count of partners | Standard Deviation 1.3 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 8.1 count of partners | Standard Deviation 15.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.8 count of partners | Standard Deviation 1.3 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 4.3 count of partners | Standard Deviation 10.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.3 count of partners | Standard Deviation 1 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 3.8 count of partners | Standard Deviation 6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.8 count of partners | Standard Deviation 2.8 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 3.3 count of partners | Standard Deviation 8.1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.6 count of partners | Standard Deviation 0.8 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.9 count of partners | Standard Deviation 1.2 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.4 count of partners | Standard Deviation 1.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 1.6 count of partners | Standard Deviation 5.5 |
Secondary
Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through month 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1.2 count of partners | Standard Deviation 0.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.5 count of partners | Standard Deviation 1.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.3 count of partners | Standard Deviation 0.7 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.4 count of partners | Standard Deviation 0.8 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 0.9 count of partners | Standard Deviation 0.6 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.1 count of partners | Standard Deviation 0.7 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.1 count of partners | Standard Deviation 0.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1.5 count of partners | Standard Deviation 0.7 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.8 count of partners | Standard Deviation 1.4 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.8 count of partners | Standard Deviation 1.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.0 count of partners | Standard Deviation 0.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.4 count of partners | Standard Deviation 0.8 |
Secondary
Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through month 3
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 2.1 count of partners | Standard Deviation 1.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 3.1 count of partners | Standard Deviation 3.8 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 1.2 count of partners | Standard Deviation 2.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 1.3 count of partners | Standard Deviation 2.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 0.9 count of partners | Standard Deviation 0.7 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.8 count of partners | Standard Deviation 1.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.4 count of partners | Standard Deviation 1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1.9 count of partners | Standard Deviation 1.1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 2.6 count of partners | Standard Deviation 7.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 4.4 count of partners | Standard Deviation 9.2 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.8 count of partners | Standard Deviation 1.9 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.5 count of partners | Standard Deviation 0.8 |
Secondary
Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through month 6
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 2.7 count of partners | Standard Deviation 4.6 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 5.2 count of partners | Standard Deviation 10.7 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 1.3 count of partners | Standard Deviation 3.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 2.0 count of partners | Standard Deviation 5.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.4 count of partners | Standard Deviation 1.4 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 3.2 count of partners | Standard Deviation 7.5 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.5 count of partners | Standard Deviation 1.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 2.2 count of partners | Standard Deviation 1.8 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 1.0 count of partners | Standard Deviation 1.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 2.7 count of partners | Standard Deviation 2.1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.7 count of partners | Standard Deviation 1.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.7 count of partners | Standard Deviation 1.2 |
Secondary
Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through month 9
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 2.0 count of partners | Standard Deviation 1.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 6.3 count of partners | Standard Deviation 14 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.6 count of partners | Standard Deviation 1 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 3.3 count of partners | Standard Deviation 9.8 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.4 count of partners | Standard Deviation 0.8 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 3.0 count of partners | Standard Deviation 6.1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.4 count of partners | Standard Deviation 1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 2.1 count of partners | Standard Deviation 1.8 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 1.2 count of partners | Standard Deviation 2.1 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 2.8 count of partners | Standard Deviation 3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.6 count of partners | Standard Deviation 1.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.7 count of partners | Standard Deviation 1.7 |
Secondary
Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through week 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1 count of partners | Standard Deviation 0 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.7 count of partners | Standard Deviation 1.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.3 count of partners | Standard Deviation 0.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.7 count of partners | Standard Deviation 1.2 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 0.7 count of partners | Standard Deviation 0.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 1.0 count of partners | Standard Deviation 0 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.3 count of partners | Standard Deviation 1.6 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1.5 count of partners | Standard Deviation 1.5 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.5 count of partners | Standard Deviation 0.7 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.0 count of partners | Standard Deviation 0 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 0.5 count of partners | Standard Deviation 0.7 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.3 count of partners | Standard Deviation 0.5 |
Secondary
Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire
Sex history since last visit
Time frame: Through week 2
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1.0 count of partners | Standard Deviation 0 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.3 count of partners | Standard Deviation 0.8 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.2 count of partners | Standard Deviation 0.4 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.5 count of partners | Standard Deviation 0.5 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 0.8 count of partners | Standard Deviation 0.4 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 0.8 count of partners | Standard Deviation 0.8 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (HIV-infected) | 1.3 count of partners | Standard Deviation 2 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (HIV-infected) | 1.9 count of partners | Standard Deviation 2.3 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (non HIV-infected) | 0.2 count of partners | Standard Deviation 0.4 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Total number of partners since last visit (non HIV-infected) | 1.0 count of partners | Standard Deviation 0 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of continuing partners since last visit (Non HIV-infected) | 0.8 count of partners | Standard Deviation 0.4 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire | Number of new partners since last visit (HIV-infected) | 0.6 count of partners | Standard Deviation 0.9 |
Secondary
Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire
Years of formal education
Time frame: Day 1
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire | HIV-infected | 37.5 years | Standard Deviation 11.9 |
| One Dose BPG 2.4 MU | Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire | HIV-uninfected | 33.4 years | Standard Deviation 11.5 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire | HIV-infected | 36.5 years | Standard Deviation 9.7 |
| Three Doses BPG 2.4 MU | Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire | HIV-uninfected | 30.1 years | Standard Deviation 10.2 |
Secondary
Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection
Serological response to therapy by Month 12 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 12 visit window (i.e., scheduled visits up to and including the Month 12 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 12 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 12visit window (i.e., seroreversion). Serological response to therapy by Month 12 was examined among participants with and without HIV infection,
Time frame: Through month 12
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| One Dose BPG 2.4 MU | Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection | HIV-infected | 55 Participants |
| One Dose BPG 2.4 MU | Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection | HIV-uninfected | 40 Participants |
| Three Doses BPG 2.4 MU | Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection | HIV-infected | 60 Participants |
| Three Doses BPG 2.4 MU | Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection | HIV-uninfected | 30 Participants |
Comparison: The number and proportion of participants with a serological response by month 12 among participants with HIV infection and the 95% confidence interval (CI) were summarized overall and by treatment status. The Farrington-Manning test at the 5% one-sided level of significance was used to test the noninferiority hypothesis. The null hypothesis was that the difference in serological response rate between the three-dose and one-dose groups was at least 10%.p-value: 0.01190% CI: [-0.18, 0.05]Farrington-Manning
Comparison: The number and proportion of participants with a serological response by month 12 amont participants without HIV infection and the 95% confidence interval (CI) were summarized overall and by treatment status. The Farrington-Manning test at the 5% one-sided level of significance was used to test the noninferiority hypothesis. The null hypothesis was that the difference in serological response rate between the three-dose and one-dose groups was at least 10%.p-value: 0.06490% CI: [-0.18, 0.11]Farrington-Manning
Secondary
Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection
Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion). Serological response to therapy by Month 6 was examined among participants with and without HIV infection,
Time frame: Day 1 to Day 180
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.~Participants with unknown HIV status not included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| One Dose BPG 2.4 MU | Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection | HIV-infected | 53 Participants |
| One Dose BPG 2.4 MU | Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection | HIV-uninfected | 39 Participants |
| Three Doses BPG 2.4 MU | Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection | HIV-infected | 59 Participants |
| Three Doses BPG 2.4 MU | Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection | HIV-uninfected | 28 Participants |
Comparison: The number and proportion of participants with serological response by month 6 among participants with HIV infection and the 95% confidence interval (CI) were summarized overall and by treatment status. The Farrington-Manning test at the 5% one-sided level of significance was used to test the noninferiority hypothesis. The null hypothesis was that the difference in serological response rate between the three-dose and one-dose groups was at least 10%.p-value: 0.02290% CI: [-0.17, 0.07]Farrington-Manning
Comparison: The number and proportion of participants with serological response by month 6 among participants without HIV infection and the 95% confidence interval (CI) were summarized overall and by treatment status. The Farrington-Manning test at the 5% one-sided level of significance was used to test the noninferiority hypothesis. The null hypothesis was that the difference in serological response rate between the three-dose and one-dose groups was at least 10%.p-value: 0.03790% CI: [-0.22, 0.09]Farrington-Manning
Secondary
Number of Participants With Serological Response (Defined as Either a 4-fold or Greater Decline in Rapid Plasma Regain (RPR) Titer Compared to Baseline or Being Rapid Plasma Regain -Negative [Seroreversion]) by Month 12.
Serological response to therapy by Month 12 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 12 visit window (i.e., scheduled visits up to and including the Month 12 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 12 visit window) were evaluated: * 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 12 visit window compared to baseline, OR * RPR-negative at any visit prior to the end of the Month 12 visit window (i.e., seroreversion).
Time frame: Through month 12
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| One Dose BPG 2.4 MU | Number of Participants With Serological Response (Defined as Either a 4-fold or Greater Decline in Rapid Plasma Regain (RPR) Titer Compared to Baseline or Being Rapid Plasma Regain -Negative [Seroreversion]) by Month 12. | 97 Participants |
| Three Doses BPG 2.4 MU | Number of Participants With Serological Response (Defined as Either a 4-fold or Greater Decline in Rapid Plasma Regain (RPR) Titer Compared to Baseline or Being Rapid Plasma Regain -Negative [Seroreversion]) by Month 12. | 91 Participants |
Comparison: The number and proportion of participants with a serological response by Month 12 and the 95% confidence interval (CI) were summarized overall and by treatment. The Farrington-Manning test at the 5% one-sided level of significance was used to test the noninferiority hypothesis. The null hypothesis was that the difference in serological response rate between the three-dose and one-dose groups was at least 10%.p-value: 0.00290% CI: [-0.14, 0.04]Farrington-Manning
Secondary
The Number of Participants Who Receive All Assigned Doses Within the Assigned Visit Windows
Compliance with study product will be defined as the participant received all assigned doses within the assigned visit windows. A participant is not adherent to study product if they miss at least one dose or receive at least one dose out of the visit window.
Time frame: Through Month 12
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| One Dose BPG 2.4 MU | The Number of Participants Who Receive All Assigned Doses Within the Assigned Visit Windows | 124 Participants |
| Three Doses BPG 2.4 MU | The Number of Participants Who Receive All Assigned Doses Within the Assigned Visit Windows | 97 Participants |
Comparison: The number and proportion of participants who were compliant to the treatment, receiving all assigned doses within the assigned visit windows. The null hypothesis was no difference between two treatment groups.p-value: <0.001Chi-squared
Secondary
The Number of Participants Who Report Jarisch-Herxheimer Reaction Manifestations
Approximately 24 hours after Visit 1, participants were contacted and evaluated for symptoms of a JHR, which included fever, chills, myalgia, weakness, flushing, worsening of skin rash, tachycardia, heart palpitations, arthralgia, nausea, headache, and dizziness, including time of onset and time of resolution of each symptom reported.
Time frame: Day 1 through Day 2
Population: The ITT Population includes all randomized subjects, regardless of whether they received study treatment or were compliant with the administration procedures or schedule.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| One Dose BPG 2.4 MU | The Number of Participants Who Report Jarisch-Herxheimer Reaction Manifestations | 27 Participants |
| Three Doses BPG 2.4 MU | The Number of Participants Who Report Jarisch-Herxheimer Reaction Manifestations | 32 Participants |